Stocktoria

COOPER COMPANIES, INC. COO

Nasdaq · XNAS · stock · Ophthalmic Goods
Chart by TradingView
6/9
Piotroski F — financial health
4.99
Altman Z″ — distress risk · safe
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$4.1B$374.9M$2.7B$433.7M$8.2B
2024$3.9B$392.3M$2.6B$288.1M$8.1B
2023$3.6B$294.2M$2.4B$215.0M$7.6B
2022$3.3B$385.8M$2.1B$450.4M$7.2B
2021$2.9B$2.9B$2.0B$524.2M$6.9B
2020$2.4B$238.4M$1.5B$176.2M$3.8B

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Rosebrough Walter M Jrdirector2026-04-01Option exercise832
WEISS ROBERT Sdirector2026-04-01Option exercise3,654
Rivas Mariadirector2026-04-01Option exercise3,322
Jay Colleendirector2026-04-01Option exercise3,322
Carbone Barbaradirector2026-04-01Option exercise3,050
MADDEN TERESA Sdirector2026-04-01Option exercise3,322
Lucchese Cynthia Ldirector2026-04-01Option exercise3,322
Kurzius Lawrence Erikdirector2026-04-01Option exercise3,322

Why these scores methodology →

Piotroski F-score: 6/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 4.99 (safe)

  • Working capital / assets 0.08
  • Retained earnings / assets 0.617
  • EBIT / assets 0.055
  • Equity / liabilities 1.983

Source: SEC EDGAR filings · CIK 0000711404 · as of 2025-10-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.